Natera, Inc. (NASDAQ:NTRA) Receives $330.83 Average PT from Analysts

Natera, Inc. (NASDAQ:NTRA) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-three research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $330.8333.

Several equities analysts have recently commented on the stock. UBS Group upped their price objective on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Citigroup raised their price target on Natera from $315.00 to $365.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Royal Bank Of Canada raised Natera from an “outperform” rating to a “buy” rating in a research note on Tuesday, September 8th. Barclays restated an “overweight” rating and set a $340.00 target price on shares of Natera in a report on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Friday, July 17th.

Insider Buying and Selling at Natera

In related news, insider John Fesko sold 6,517 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the completion of the transaction, the insider directly owned 197,257 shares of the company’s stock, valued at $63,424,043.21. The trade was a 3.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 15,160 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total value of $4,955,652.40. Following the sale, the insider owned 110,859 shares in the company, valued at approximately $36,238,698.51. This trade represents a 12.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 68,242 shares of company stock valued at $19,301,534 in the last 90 days. Corporate insiders own 5.05% of the company’s stock.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently made changes to their positions in NTRA. Parallel Advisors LLC raised its holdings in Natera by 5.5% in the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 47 shares during the last quarter. Raiffeisen Bank International AG boosted its holdings in shares of Natera by 48.5% during the second quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company’s stock worth $41,000 after purchasing an additional 49 shares during the last quarter. First Horizon Corp boosted its holdings in shares of Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after purchasing an additional 51 shares during the last quarter. Alamea Verwaltungs GmbH grew its position in shares of Natera by 2.9% in the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after purchasing an additional 62 shares during the period. Finally, Kestra Private Wealth Services LLC increased its stake in Natera by 5.3% in the first quarter. Kestra Private Wealth Services LLC now owns 1,246 shares of the medical research company’s stock valued at $249,000 after purchasing an additional 63 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Price Performance

Shares of NASDAQ NTRA opened at $366.31 on Tuesday. The company has a 50 day simple moving average of $303.46 and a 200-day simple moving average of $245.83. The company has a market capitalization of $52.80 billion, a P/E ratio of -269.34 and a beta of 1.54. Natera has a 1 year low of $157.43 and a 1 year high of $366.70.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.74) EPS. As a group, research analysts expect that Natera will post -1.02 EPS for the current year.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services based on cell-free DNA and other genomic technologies. The company focuses on reproductive health, oncology and organ health, providing tests intended to support screening, diagnosis, treatment planning and disease monitoring.

Its reproductive health portfolio includes Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test.